Clinical trial
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual…
NCT00362817 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00362817 |
|---|---|
| Title | Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases |
| Official title | Phase I/II Multicenter Trial of Intra-Arterial Carboplatin and Oral Temozolomide for the Treatment of Recurrent and Symptomatic Residual Brain Metastases. |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain Tumor, Brain Metastases |
| Intervention type | Drug |
| Interventions | carboplatin, temozolomide |
| Enrollment | 17 |
| Start date | Oct 1, 2004 |
| Primary completion | Jan 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Aug 10, 2006 |
| Last update posted | Jun 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: